Discussion
nasal airflow
SARS-COV-2 INFECTION, COMMON COLDS, COLD SYMPTOM, COMMON COLD, SECONDARY, CAVITY
Previous research results evaluating ColdZyme and oral mouth rinses on common cold viruses and SARS-CoV-2 infections show all have The design of the previous and present trials was similar to several other studies assessing interventions at the first sign of self-perceived common colds illness [The previous single-blind trial determined common cold symptom durations of 6.3 and 7.1 days (treatment) and 7.1 and 8.1 days (no treatment) using two measures of duration; number of days from symptom start until the last day before answering “No” to the question “Do you think that you still have a common cold”, and number of days with a total Jackson score > zero [Design limitations of this trial may have acted to reduce the ability to appreciate differences between placebo and ColdZyme treated groups affecting the primary and major secondary variables. First, the placebo spray containing menthol may have signaled a perception of efficacy in the placebo-treated subjects as sixty percent at the end of the study rated efficacy as “very good” or “good”, thereby lessening differences with active treatment. Topical menthol is well-known to act on mucosal TRPM8 sensory receptors in the oropharyngeal cavity, perceived as cooling sensations that provide an increased sensation of nasal airflow, improve physiological performance, and give a sense of reward [